[Federal Register Volume 65, Number 201 (Tuesday, October 17, 2000)]
[Notices]
[Page 61352]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-26582]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

  


Prospective Grant of Exclusive License: Insulin Producing Cells 
Differentiated from Non-Insulin Producing Cells by GLP-1 and Exendin-4 
and Use Thereof

  
AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
PCT Patent Application Serial Number PCT/US99/180899 (PHS Ref. E-151-
97/1) entitled ``Insulin Producing Cells Differentiated from Non-
Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof'' filed 
on August 18, 1999, claiming priority of August 10, 1998, to Amylin 
Pharmaceuticals, Inc., having a place of business in San Diego, CA. The 
patent rights in this invention have been assigned to the United States 
America.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before December 
18, 2000 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: John Rambosek, Ph.D., Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Email: <a href="/cdn-cgi/l/email-protection#3c564e0f0d0e587c525554125b534a"><span class="__cf_email__" data-cfemail="91fbe3a2a0a3f5d1fff8f9bff6fee7">[email protected]</span></a>; Telephone: 
(301) 496-7056, ext. 270; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The patent application relates to a 
population of insulin producing cells differentiated from non-insulin 
producing cells by contacting the non-insulin producing cells with 
Glucagon-like peptide-1 (GLP-1), Exendin-4, or related peptides. The 
application also relates to the methods for obtaining the insulin 
producing cells and therapeutic uses in the treatment of diabetes 
mellitus.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be limited to the field of use 
for development of products and methods for treatment of diabetes. The 
field for use would include development, use, manufacture, 
distribution, import, export, marketing and sale of the licensed 
invention, throughout the world. The prospective exclusive license may 
be granted unless, within 60 days from the date of this published 
Notice, NIH receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 5, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-26582 Filed 10-16-00; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>